Pediatric Oncology

CAR-T

Questions discussed in this category

Is there a role for IL2-receptor antagonists and TNF-alpha inhibitors in cytokine release syndrome as a complication of CAR-T or immunotherapy?

1 Answer available

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

1 Answer available

What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?

1 Answer available

How do you determine when to give a second CAR-T cell infusion to a pediatric or young adult patient with relapsed/refractory ALL?

2 Answers available

Do you offer fertility preservation to patients prior to CAR-T therapy?

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

1 Answer available

Papers discussed in this category

Blood, 2020 Sep 23

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

J Clin Oncol, 2021 Dec 9

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Blood Cancer Discov, 2021 Dec 01

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Exp Hematol Oncol, 2021 Feb 19

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.

Related Topics in Pediatric Oncology